Phase I, Open-Label, 3-Way Crossover Trial in Healthy Male Volunteers to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-Release Coformulations as Compared to an Immediate-Release Coformulation of TMC114/TMC41629.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Darunavir/TMC 41629 (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 09 Mar 2009 New trial record